Novacyt Sa Stock EBITDA
| NVYTF Stock | USD 0.63 0.02 3.28% |
Novacyt SA fundamentals help investors to digest information that contributes to Novacyt SA's financial success or failures. It also enables traders to predict the movement of Novacyt Pink Sheet. The fundamental analysis module provides a way to measure Novacyt SA's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Novacyt SA pink sheet.
Novacyt |
Novacyt SA Company EBITDA Analysis
Novacyt SA's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Novacyt SA EBITDA | (1.71 M) |
Most of Novacyt SA's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novacyt SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
According to the company disclosure, Novacyt SA reported earnings before interest,tax, depreciation and amortization of (1.71 Million). This is 100.19% lower than that of the Healthcare sector and 100.27% lower than that of the Medical Devices industry. The ebitda for all United States stocks is 100.04% higher than that of the company.
Novacyt EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novacyt SA's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Novacyt SA could also be used in its relative valuation, which is a method of valuing Novacyt SA by comparing valuation metrics of similar companies.Novacyt SA is currently under evaluation in ebitda category among its peers.
Novacyt Fundamentals
| Return On Equity | -0.0198 | |||
| Return On Asset | 0.0145 | |||
| Profit Margin | (0.1) % | |||
| Operating Margin | 0.07 % | |||
| Current Valuation | (50.49 M) | |||
| Shares Outstanding | 70.63 M | |||
| Shares Owned By Insiders | 3.49 % | |||
| Shares Owned By Institutions | 1.60 % | |||
| Price To Earning | 0.51 X | |||
| Price To Book | 0.40 X | |||
| Price To Sales | 1.04 X | |||
| Revenue | 95.78 M | |||
| Gross Profit | 64.87 M | |||
| EBITDA | (1.71 M) | |||
| Net Income | (9.73 M) | |||
| Cash And Equivalents | 99.65 M | |||
| Cash Per Share | 1.41 X | |||
| Total Debt | 1.67 M | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 4.66 X | |||
| Book Value Per Share | 1.88 X | |||
| Cash Flow From Operations | 15.69 M | |||
| Earnings Per Share | (0.17) X | |||
| Number Of Employees | 210 | |||
| Beta | -2.16 | |||
| Market Capitalization | 83.34 M | |||
| Total Asset | 183.7 M | |||
| Z Score | 29.4 | |||
| Net Asset | 183.7 M |
About Novacyt SA Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Novacyt SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novacyt SA using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novacyt SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Novacyt Pink Sheet
Novacyt SA financial ratios help investors to determine whether Novacyt Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Novacyt with respect to the benefits of owning Novacyt SA security.